Express News | Intra-Cellular Therapies Inc - Sandoz to Sell Generic Caplyta From July 1, 2040

Reuters06:31 ET

Intra-Cellular Therapies Settles CAPLYTA (Lumateperone) Patent Litigation With Sandoz

GlobeNewswire06:30 ET

Express News | Intra-Cellular Therapies Settles Caplyta® (Lumateperone) Patent Litigation With Sandoz

Reuters06:30 ET

RBC Capital Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Cuts Target Price to $108

Moomoo NewsJan 7 09:35 ET · Ratings

RBC Trims Price Target on Intra-Cellular Therapies to $108 From $112, Keeps Outperform Rating

MT NewswiresJan 7 07:08 ET · Ratings

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswireJan 6 08:00 ET